Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 Due to a ... last week, the Adult Stem Cell Technology Center, LLC ( ... support stem cell therapy research that might benefit ALS patients. ... cells for new stem cell technologies and therapeutic applications, FRC ... Ice Bucket Challenge donors who wish not to support ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... business delivers record growth; biofuels business, advancing ... Mass., May 5 Verenium Corporation,(Nasdaq: VRNM ... cellulosic,ethanol and high-performance specialty enzymes, today reported financial,results ... updated 2008 financial,guidance., "I am encouraged by ...
... 37.5% to $14.8 Million ... ... Guidance, MINNEAPOLIS, May 5 ATS Medical, Inc. (Nasdaq:,ATSI), manufacturer ... results for the first,quarter ended March 29, 2008. Revenue for the ...
... May 5 Assay Designs, Inc., a leading,provider ... life sciences,and translational research markets, announced a collaboration ... University of South Carolina and,Dr. Jennifer Isaacs, laboratory. ... provide anti-Heat shock protein 90 (Hsp90) antibody for ...
Cached Biology Technology:Verenium Reports Financial Results for the First Quarter 2008 2Verenium Reports Financial Results for the First Quarter 2008 3Verenium Reports Financial Results for the First Quarter 2008 4Verenium Reports Financial Results for the First Quarter 2008 5Verenium Reports Financial Results for the First Quarter 2008 6Verenium Reports Financial Results for the First Quarter 2008 7Verenium Reports Financial Results for the First Quarter 2008 8Verenium Reports Financial Results for the First Quarter 2008 9Verenium Reports Financial Results for the First Quarter 2008 10Verenium Reports Financial Results for the First Quarter 2008 11ATS Medical Announces Record Quarterly Revenue and Gross Profit 2ATS Medical Announces Record Quarterly Revenue and Gross Profit 3ATS Medical Announces Record Quarterly Revenue and Gross Profit 4ATS Medical Announces Record Quarterly Revenue and Gross Profit 5ATS Medical Announces Record Quarterly Revenue and Gross Profit 6ATS Medical Announces Record Quarterly Revenue and Gross Profit 7ATS Medical Announces Record Quarterly Revenue and Gross Profit 8ATS Medical Announces Record Quarterly Revenue and Gross Profit 9Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC) 2
(Date:8/28/2014)... is needed to ensure safeguards are in place to ... PLOS ONE , researchers from Monash University, Stellenbosch University ... results from different studies - to look at the ... determine whether they actually protect biodiversity. , Dr ... area from human exploitation made common sense, however, up ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Law Enforcement ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About Biometrics ... individuals on the basis of their physical or ... of both physiological traits such as fingerprints, face ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... 20, 2011 Whether engaging experts from the outside to ... AIDS, leaders around the globe acknowledge the need to innovate ... facing business and society today. NineSigma, the leading provider of ... the imperative to innovate for organizations is greater than ever, ...
... Gulf of Mexico is safe to eat after the Deepwater ... testing program that continues more than a year after the ... by Federal agencies to assure safety of Gulf seafood is ... of Chemical & Engineering News (C&EN), ACS,s weekly news magazine. ...
... A new genus and species of hadrosaur (duck-billed) dinosaur ... has been named by scientists who expect the ... most striking feature of Acristavus gagslarsoni , the ... head lacked the distinctive ornamentation common to later duck-billed ...
Cached Biology News:NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 2NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 3NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 4New duck-billed dinosaur gives scientists clues to evolution of head ornamentation and provinciality 2
Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
... monoclonal [F30 P7 D7 F5] to ... tested applications). Antigen: ... Ovalbumin, corresponding to amino acids 462 ... Entrez Gene ID: 6259 ...
E2F-5...
LAB/Probe Mouse-Rabbit DAB Kit...
Biology Products: